Sunshine Biopharma (SBFM) Non-Current Debt (2017 - 2021)

Sunshine Biopharma has reported Non-Current Debt for 5 years, with the latest figure at $1.9 million in Q4 2021.

• For the quarter ending Q4 2021, Non-Current Debt rose 100.21% year-over-year to $1.9 million; the trailing twelve-month figure through Dec 2021 stood at $1.9 million (up 100.21% YoY), and the FY2021 full-year result was $1.9 million, up 100.21% from the prior year.
• Non-Current Debt for Q4 2021 stood at $1.9 million, down from $3.2 million in the prior quarter.
• The five-year high for Non-Current Debt was $3.2 million in Q3 2021, with the low at $63234.0 in Q2 2020.
• Historically, Non-Current Debt has averaged $1.1 million across 5 years, with a median of $357552.0 in 2020.
• The largest YoY upside for Non-Current Debt was 3148.59% in 2021 against a maximum downside of 100.21% in 2021.
• Sunshine Biopharma's Non-Current Debt stood at $79710.0 in 2017, then soared by 263.63% to $289847.0 in 2018, then decreased by 0.01% to $289825.0 in 2019, then soared by 227.44% to $949006.0 in 2020, then surged by 100.21% to $1.9 million in 2021.
• The last three Non-Current Debt figures came in at $1.9 million (Q4 2021), $3.2 million (Q3 2021), and $2.1 million (Q2 2021), per Business Quant data.